vs
Side-by-side financial comparison of Alpha Cognition Inc. (ACOG) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $2.8M, roughly 1.7× Alpha Cognition Inc.). MAXCYTE, INC. runs the higher net margin — -200.5% vs -245.5%, a 45.0% gap on every dollar of revenue. MAXCYTE, INC. produced more free cash flow last quarter ($-2.9M vs $-7.1M).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
ACOG vs MXCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8M | $4.8M |
| Net Profit | $-6.9M | $-9.6M |
| Gross Margin | — | — |
| Operating Margin | -283.7% | -234.5% |
| Net Margin | -245.5% | -200.5% |
| Revenue YoY | — | -20.9% |
| Net Profit YoY | — | 9.4% |
| EPS (diluted) | $-0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8M | $4.8M | ||
| Q3 25 | $2.8M | $4.6M | ||
| Q2 25 | $1.7M | $5.8M | ||
| Q1 25 | $2.9M | $5.7M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | — | $5.0M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | $-6.9M | $-9.6M | ||
| Q3 25 | $-1.3M | $-12.4M | ||
| Q2 25 | $-10.5M | $-12.4M | ||
| Q1 25 | $-2.0M | $-10.3M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | — | $-11.6M | ||
| Q2 24 | — | $-9.4M | ||
| Q1 24 | — | $-9.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 96.7% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -283.7% | -234.5% | ||
| Q3 25 | -187.0% | -307.4% | ||
| Q2 25 | -346.1% | -244.3% | ||
| Q1 25 | -125.9% | -214.1% | ||
| Q4 24 | — | -213.1% | ||
| Q3 24 | — | -250.4% | ||
| Q2 24 | — | -241.0% | ||
| Q1 24 | — | -219.8% |
| Q4 25 | -245.5% | -200.5% | ||
| Q3 25 | -46.4% | -269.7% | ||
| Q2 25 | -632.7% | -212.2% | ||
| Q1 25 | -68.5% | -178.7% | ||
| Q4 24 | — | -175.0% | ||
| Q3 24 | — | -205.9% | ||
| Q2 24 | — | -188.8% | ||
| Q1 24 | — | -170.6% |
| Q4 25 | $-0.10 | — | ||
| Q3 25 | $-0.30 | $-0.12 | ||
| Q2 25 | $-0.65 | $-0.12 | ||
| Q1 25 | $-0.13 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.0M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $62.5M | $171.5M |
| Total Assets | $79.7M | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.0M | $103.0M | ||
| Q3 25 | $35.4M | $105.7M | ||
| Q2 25 | $39.4M | $126.6M | ||
| Q1 25 | $45.5M | $138.3M | ||
| Q4 24 | — | $154.5M | ||
| Q3 24 | — | $153.8M | ||
| Q2 24 | — | $157.3M | ||
| Q1 24 | — | $157.5M |
| Q4 25 | $62.5M | $171.5M | ||
| Q3 25 | $33.9M | $180.3M | ||
| Q2 25 | $31.9M | $190.7M | ||
| Q1 25 | $40.8M | $199.4M | ||
| Q4 24 | — | $206.3M | ||
| Q3 24 | — | $213.3M | ||
| Q2 24 | — | $221.3M | ||
| Q1 24 | — | $226.4M |
| Q4 25 | $79.7M | $202.5M | ||
| Q3 25 | $46.3M | $213.5M | ||
| Q2 25 | $45.1M | $219.8M | ||
| Q1 25 | $48.6M | $230.0M | ||
| Q4 24 | — | $239.5M | ||
| Q3 24 | — | $248.6M | ||
| Q2 24 | — | $251.5M | ||
| Q1 24 | — | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.9M | $-2.7M |
| Free Cash FlowOCF − Capex | $-7.1M | $-2.9M |
| FCF MarginFCF / Revenue | -252.6% | -61.0% |
| Capex IntensityCapex / Revenue | 5.3% | 4.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-20.7M | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.9M | $-2.7M | ||
| Q3 25 | $-5.3M | $-7.5M | ||
| Q2 25 | $-6.1M | $-9.9M | ||
| Q1 25 | $-2.0M | $-14.4M | ||
| Q4 24 | — | $-7.8M | ||
| Q3 24 | — | $-4.4M | ||
| Q2 24 | — | $-4.8M | ||
| Q1 24 | — | $-10.6M |
| Q4 25 | $-7.1M | $-2.9M | ||
| Q3 25 | $-5.4M | $-7.8M | ||
| Q2 25 | $-6.1M | $-10.4M | ||
| Q1 25 | $-2.1M | $-15.1M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-11.4M |
| Q4 25 | -252.6% | -61.0% | ||
| Q3 25 | -188.8% | -168.5% | ||
| Q2 25 | -370.9% | -179.2% | ||
| Q1 25 | -72.0% | -262.3% | ||
| Q4 24 | — | -131.6% | ||
| Q3 24 | — | -85.5% | ||
| Q2 24 | — | -103.3% | ||
| Q1 24 | — | -203.6% |
| Q4 25 | 5.3% | 4.8% | ||
| Q3 25 | 2.6% | 6.5% | ||
| Q2 25 | 0.5% | 10.0% | ||
| Q1 25 | 2.2% | 11.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 14.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACOG
Segment breakdown not available.
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
